NEW YORK--(BUSINESS WIRE)--May 3, 2005--Rodman & Renshaw, LLC today announces the appointment of two prominent healthcare analysts to its life-sciences research team. Michael G. King, Jr., who is recognized among his peers as one of the sell-side’s most authoritative voices on the life-sciences industry, joins Rodman & Renshaw after nearly three years as a managing director and senior biotechnology analyst at Banc of America Securities LLC (BofA). During his tenure at BofA, Mr. King was ranked #11 in the 2004 Institutional Investor All-Star Poll, and also ranked as runner-up in the hedge fund portion of the survey. Prior to BofA, Mr. King served as a managing director and senior biotechnology analyst at Robertson Stephens. He served in a similar capacity for three years at Vector Securities International. Mr. King has also been affiliated with Kidder, Peabody, Hambrecht and Quist, Alex Brown & Sons, and D. Blech and Co. At Rodman & Renshaw, Mr. King will cover a wide variety of life-sciences companies, ranging from micro-cap opportunities to the large-cap industry leaders.
